Edition:
United States

Novavax Inc (NVAX.O)

NVAX.O on Nasdaq

6.67USD
20 Aug 2019
Change (% chg)

$-0.62 (-8.50%)
Prev Close
$7.29
Open
$7.02
Day's High
$7.05
Day's Low
$6.43
Volume
1,569,155
Avg. Vol
926,947
52-wk High
$51.60
52-wk Low
$4.01

About

Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates... (more)

Overall

Beta: 1.98
Market Cap(Mil.): $338.31
Shares Outstanding(Mil.): 294.18
Dividend: --
Yield (%): --

Financials

  NVAX.O Industry Sector
P/E (TTM): -- 69.38 32.67
EPS (TTM): -0.77 -- --
ROI: -57.83 8.94 14.48
ROE: -829.23 10.07 15.78

Novavax shares plunge 65 percent as respiratory vaccine fails in late-stage trial

Novavax Inc shares crashed 65 percent on Thursday after data showed its vaccine failed to prevent RSV disease, a leading cause of respiratory infections in infants, missing the main goal of a late-stage study.

Feb 28 2019

UPDATE 1-Novavax respiratory infection vaccine fails in late-stage trial

Feb 28 Novavax Inc said on Thursday its vaccine to prevent RSV infection, a leading cause of a respiratory disease in infants, failed to meet the main goal of a late stage study.

Feb 28 2019

Novavax's respiratory infection vaccine fails in late-stage trial

Feb 28 Novavax Inc said on Thursday its vaccine to prevent RSV infection, a leading cause of a respiratory disease in infants, failed to meet the main goal of a late stage study.

Feb 28 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates